Immune Response Remune Trials To Continue After Agouron Drops Rights
Executive Summary
Immune Response Corporation will continue clinical trials for the HIV therapy Remune (HIV-1 immunogen) following the decision by Pfizer subsidiary Agouron to drop its rights to develop and market the product, IRC said July 6.